22 NovChemical Science Graduate SeminarZoom Webinar: The Alliance of Biological Drugs and Nanomedicine
Zoom Webinar: The Alliance of Biological Drugs and Nanomedicine
  • Professor Maria José Alonso
  • University of Santiago de Compostela (USC), Spain
  • Sunday, November 22, 2020
  • 12:00 PM - 01:00 PM
  • KAUST, VIA ZOOM, CLICK OR COPY THE LINK BELOW
2020-11-22T12:002020-11-22T13:00Asia/RiyadhZoom Webinar: The Alliance of Biological Drugs and NanomedicineChemS Graduate Seminar Zoom Webinar: The Alliance of Biological Drugs and Nanomedicine Professor Maria José AlonsoKAUST, VIA ZOOM, CLICK OR COPY THE LINK BELOWAliyah Fakimaliyah.fakim@kaust.edu.sa

Please click the link below to join the webinar:

https://kaust.zoom.us/j/91311231633

Abstract: The continuously improved understanding of the biological barriers and the molecular biology associated to pathological conditions is paving the way for a more comprehensive and rational design of protein formulations based on the use of nanotechnology. Our laboratory, with a long-track experience in the formulation of macromolecules using polymer nanoparticles, has significantly contributed to this field. As an example, in the 90’s we were the first to report that nanoparticles made of either PLA-PEG or chitosan were efficient vehicles for the transmucosal delivery of proteins and antigens. The result of our subsequent efforts is an array of nanotechnologies that can be used to deliver proteins across mucosal surfaces, and, also, to facilitate their intracellular delivery following parenteral administration. 


In my presentation, I will focus on the design of protein carriers that could be used in different therapeutic areas: (i) oral delivery of peptides intended to treat either local or systemic diseases, (ii) delivery of mAb targeted to intracellular onco-proteins, as new oncological treatments, (iii) nanovaccines designed to prevent diseases, i.e. HIV.


Overall, our experience in this field has benefited from integrative approaches adopted by specifically designed consortia. Hopefully, the results of these cooperative efforts will help to accelerate the progress of a rational design of protein-based nanomedicines.

More information about these projects can be found at:

http://www.usc.es/grupos/mjalonsolab/


Acknowledgements:

The following researchers have contributed to the work in different fields:

Oral protein delivery: Matilde Duran, Eleni Samaridou, Carlos Dieguez, Sulay Tovar, Niu Zhigao and Manuel Santander from the USC, Aloise Mabonzo, from the CEA, France and Patrik Lundquist and Per Artursson from UU, Sweden. 

Vaccine delivery: Jose Crecente, Tamara Gómez, Ana Olivera and Dolores Torres from the USC, Africa González from the University of Vigo and Ma Luo and Frank Plummer from University of Manitoba, Canada.

Nose-to-brain delivery: Eleni Samaridou and Vanessa Castro from USC, and Hannah Walgrave and Evgenia Salta from VIB–Leuven, Leuven, Belgium.

Delivery of anti-cancer monoclonal antibodies: Ana Cadete, Ana Olivera, Desirée Teijeiro and Dolores Torres from the USC, Spain and Gema Moreno and Angela Molina from the UAM, Spain. 


The research activity has been founded the the European Comision FP7 (grant agreement n° 281035-TRANS-INT), the Horizon 2020 Program (grant agreement # 646142 – NANOPILOT and grant agreement No. 721058- B-SMART), The National Institutes of Health (NIH) (Grant Number: R01AI111805) and the NanoFar European Doctorate, EMJD NanoFar (grant agreement # 2012-0028) and the World Cancer Research Organization.


Biography: María José Alonso’s lab has pioneered numerous discoveries in the field of Pharmaceutical Nanotechnology and nanomedicine. She has coordinated several research consortia financed by the WHO, the Gates Foundation and the European Commission. She is the author of 290 scientific contributions with more than 29,400 cites (H factor 90) and the inventor of 22 patent families. Because of the quality of her scientific articles she has been among the TOP TEN in Pharmacology (Times Higher Education international ranking, 2010). Recently, she become part of the “Power List” of the most influential researchers in the field of Biopharmaceuticals (The Medicine Maker, 2020)


She has served to the Release Society (CRS) for 15 years and she is currently Past President of the Controlled Release Society (CRS). She is also Editor-in-Chief of the Drug Delivery and Translational Research, an official journal of the CRS, and she is part of the editorial board of 11 journals. 


She has received 33 awards, among them the ”Research and Education Excellence Medal” granted by the Spanish Government, the “Jaime I Award”, the General Council of Pharmacy Medal, and other awards granted by scientific organizations, such as the ”Marie Junot Award” of the APGI, the “Founders Award”, the “Outstanding Service Award” and the “Women in Sciences Award” of the CRS. She was also recently awarded by the AIM-HI Women’s Venture Competition program born out of the National Foundation for Cancer Research (NFCR). 


She is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and a Fellow of the Controlled Release Society, a member of the Royal Academy of Pharmacy of Spain, the Royal Academy of Sciences of Galicia, the Royal Academy of Pharmacy in Galicia and a member of the US National Academy of Medicine (NAM).


She was the Vice-rector of Research and Innovation of the USC (2006-10).

MORE INFORMATION

  • Aliyah Fakim
  • aliyah.fakim@kaust.edu.sa

LOCATION

Top